SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as it tests key support levels, sparking debate about a potential rebound or further decline. Community discussions revolve around Michael Saylor's continued accumulation and the influence of broader market factors like potential Fed rate cuts and macroeconomic data. Some traders are pointing to technical indicators suggesting oversold conditions and a possible relief rally, while others remain bearish, citing historical patterns and potential risks.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation of a potential bidding war, with reports suggesting Paramount, Comcast, and Netflix are preparing offers. Community discussions revolve around potential buyout prices and the strategic value of WBD's assets, including HBO and Warner Bros. studios. The stock's movement reflects both optimism for a high-value deal and concerns about the company's debt.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending due to increased staking, incentives for BTCFi, and the potential for scaling privacy solutions. Community members are discussing its relationship to ZCash ($ZEC) and the possibility of a "Ztarknet", which would integrate privacy and scalability. The recent surge in staking and new developments in BTCFi are driving renewed interest in the token.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium ($SGML) is trending as investors digest recent Q3 earnings reports and insider buying activity, while lithium prices show signs of recovery. The community is weighing the company's financial health, production capacity, and potential for a price surge amidst broader discussions about the lithium market's future and potential takeover scenarios. Bullish sentiment is building, driven by rising lithium prices and the anticipation of future earnings reports.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as Bitcoin's pullback impacts the stock, leading to community discussions about its correlation with BTC and sustainability. Concerns are emerging regarding Strategy's debt and ability to cover dividend payments, with some speculating about potential liquidation risks. Despite negativity, some investors view the dip as a buying opportunity, citing the company's substantial Bitcoin holdings and potential for a rebound.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending amid speculation around its involvement in a potential TikTok deal and positive sentiment stemming from analysts highlighting its AI server business and long-term growth potential. Community discussions revolve around the company's undervaluation, its relationship with key partners, and the anticipation of new highs, despite some mixed reactions to recent price action. Upgraded financial outlook and EPS growth projections are also fueling investor interest.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

Wasatch Pharmaceutical Inc

Wasatch Pharmaceutical (WSHP) is trending due to its recent direct listing, sparking significant community discussion around potential trading opportunities. The stock's volatile price action and potential for a large percentage move are key talking points. Traders are actively monitoring the stock for entry points and potential shorting opportunities amid the heightened activity.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's stock is trending amid news of increased investment in AI and cloud infrastructure, with community members discussing its potential impact on market share and competition with other tech giants like Nvidia.  Some investors are optimistic about Alphabet's long-term growth and AI leadership, while others are wary of a potential overvaluation or bubble in the AI sector. Discussions also include contrasting opinions on the recent settlement with Epic Games and its potential effect on services revenue.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors react to Berkshire Hathaway's newly disclosed stake, signaling confidence in Alphabet's AI future and data center investments. The community is buzzing about potential all-time highs and comparing the stock's valuation to other tech giants, while some caution against overbought conditions and the lack of immediate news catalysts. Google's AI leadership and reasonable PE ratio are key talking points, with many eyeing a move towards $300.

Sociedad Quimica y Minera de Chile SA engages in the production and distribution of fertilizers, potassium nitrate, iodine, and lithium chemicals. It operates through the following segments: Specialty Plant Nutrients, Iodine and Derivatives, Lithium and Derivatives, Industrial Chemicals, Potassium, and Other Products and Services. The Specialty Plant Nutrients segment produces potassium nitrate, sodium nitrate, sodium potassium nitrate, and specialty blends. The Iodine and Derivatives segment manufactures iodine and iodine derivatives, which are used in a wide range of medical, pharmaceutical, agricultural, and industrial applications. The Lithium and Derivatives segment covers lithium carbonate for electrochemical materials for batteries, frits for the ceramic and enamel industries, heat-resistant glass, air conditioning chemicals, continuous casting powder for steel extrusion, primary aluminum smelting process, pharmaceuticals, and lithium derivatives. The Industrial Chemicals segment comprises industrial chemicals including sodium nitrate, potassium nitrate, and boric acid. The Potassium segment produces potassium chloride and potassium sulfate. The Other Products and Services segment deals with other fertilizers and blends. The company was founded on June 17, 1968 and is headquartered in Santiago, Chile.

Sociedad Quimica Y Minera de Chile S.A. - ADR

Chemical & Mining Co. of Chile Inc.

SQM is trending as investors digest news of a potential agreement with Codelco regarding lithium operations, sparking debate about the long-term benefits. Community discussions center on the impact of lithium prices and production strategies on the stock's outlook, with some analysts adjusting price targets. The stock's dividend yield and exposure to the EV battery market are also key talking points.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Pharma (NASDAQ:BBIO) Director Hannah Valantine Sells 25,484 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 25,484 shares of the business's stock in a transaction on Wednesday, November 12th. The stock was sold at an...

BridgeBio Pharma (NASDAQ:BBIO) Director Sells $1,683,727.88 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 25,484 shares of the firm's stock in a transaction on Wednesday, November 12th. The stock was sold at an average...

Los Angeles Capital Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO

Los Angeles Capital Management LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 2nd quarter, according to the company in its most recent Form...

Wells Fargo & Company Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

Wells Fargo & Company boosted their target price on BridgeBio Pharma from $76.00 to $84.00 and gave the stock an "overweight" rating in a research report on Tuesday...

BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,526,000.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an...

BridgeBio Pharma (NASDAQ:BBIO) Director Ronald Daniels Sells 61,031 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Ronald Daniels sold 61,031 shares of BridgeBio Pharma stock in a transaction on Thursday, November 6th. The stock was sold at an...

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

JPMorgan Chase & Co. lifted their price target on BridgeBio Pharma from $76.00 to $77.00 and gave the company an "overweight" rating in a research note on Friday...

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -7.95% and +14.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>The study was designed to study the efficacy and safety of Encaleret and enrolled 70 adults with ADH1.</li><li>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.</li><li>The company now plans to submit a new drug application to the U.S. Food and Drug Administration in the first half of 2026. &nbsp;</li></ul>Shares of BridgeBio Pharma, Inc. (BBIO) rose 4% on Wednesday afternoon after the company announced that its late-stage study of Encaleret in patients with autosomal dominant hypocalcemia type 1 met all primary and key secondary endpoints.This marks the company’s second positive trial result announcement this week. The Encaleret<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bridgebio.com/news/news-details/2025/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1/default.aspx"> study</a> was designed to study the efficacy and safety of the drug and enrolled 70 adults with ADH1– autosomal dominant hypocalcemia type 1 – a genetic disorder that causes low blood calcium levels, a condition known as hypocalcemia. Symptoms, which can range from none to severe, include muscle spasms, cramps, tingling sensations, and, in severe cases, seizures.<h2 class="st-heading-2">Trial Outcomes</h2>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment compared to 4% when on conventional therapy, the company said. Furthermore, the drug was well-tolerated, the company noted.The company now plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the first half of 2026, followed by an application to the European Medicines Agency.The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026. The trial in pediatric ADH1 is slated for the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BBIO">BBIO stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user termed the news great but expressed disappointment that the stock didn't rally further.<stembedurl>https://stocktwits.com/SugarSlim/message/634124724</stembedurl>Wednesday’s results come after the company <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">announced</a> on Monday that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.BBIO stock is up by 145% this year and by about 175% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results 

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

Equity

The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026.

BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BBIO News

BBIOBridgeBio Pharma Inc